Spotlight on Pulmonary/Respiratory Medicine
Managing Severe COVID-19 in the Hospital Setting: An Interprofessional Approach
StartActivity Details
0.5 ANCC Contact Hour(s)
0.5 IPCE Credit(s)™
0.5 ABIM MOC Point(s)
Expires: February 10, 2023
Provided By
RMEI Medical Education, LLC
Target Audience
This activity is intended for emergency medicine, hospital medicine, infectious disease, internal medicine, and pediatric clinicians (MD/NP/PA/Nurses) involved in the treatment of patients with severe COVID-19 infection.
Learning Objectives
Upon completion of this activity, participants should be better able to:
- Assess disease severity and implications in patients with COVID-19
- Incorporate emergency use authorization status and available clinical trial data into the selection of treatment for patients hospitalized with COVID-19
- Integrate the unique roles and responsibilities of interprofessional care team members in the management of severe COVID-19 in hospitalized patients
Activity Description
“I was dying … and I was dying alone,” says Nancy, recalling her lonely isolation in the intensive care unit as one of the earlier victims of COVID-19 in her region. This dynamic panel features an interprofessional lineup of experts who will debate and discuss data, guidelines, and literature on the treatment of severe COVID-19 in the hospital setting and what it all means for your practice and patients. Additionally, they are joined by Nancy who survived the earliest days of COVID-19 in the United States and will share her learning moments with the panel and learners.
Chair
Director, Clinical Infectious Diseases Research and MultiSpecialties
Clinical Associate Professor, Medicine (Tulane University)
Associate Professor, University of Queensland/Ochsner Clinical School, Brisbane, Australia
Ochsner Health
New Orleans, LA
Faculty
Chief, Division of Infectious Diseases
Vice-Chair, Faculty Development
Professor, Medicine
Director, San Antonio Center for Medical Mycology
UT Health San Antonio
San Antonio, TX
Advanced Practice Provider, Pulmonary Critical Care
Chairperson, System Critical Care Integration Council
Ochsner Medical Center
Ochsner Health
New Orleans, LA
Disclosure of Financial Relationships
RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy.
Faculty
Julia B. García-Díaz, MD, MSc, FACP, FIDSA, CPI, has no relevant
financial relationships with ineligible companies to disclose.
Thomas F. Patterson, MD, FACP, FIDSA, has relevant financial relationships with Appili, Basilea, Gilead, Mayne, Merck, Pfizer, Scynexis, Sfunga (Consultant); Cidara, F2G (Researcher).
Fiona A. Winterbottom, DNP, MSN, APRN, ACNS-BC, ACHPN, CCRN, has relevant financial relationships with Baxter (Advisor); Zoll (Speaker/Speaker’s Bureau).
Patient participating in this activity has no relevant financial relationship(s) with ineligible companies to disclose.
All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.
Planners and Managers
RMEI Medical Education, LLC planners and managers have no relevant financial
relationship(s) with ineligible companies to disclose.
Joint Accreditation Statement
In support
of improving patient care, RMEI Medical Education, LLC is jointly accredited
by the Accreditation Council for Continuing Medical Education (ACCME), the
Accreditation Council for Pharmacy Education (ACPE), and the American Nurses
Credentialing Center (ANCC), to provide continuing education for the
healthcare team.
Designation of Credit
Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum
of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only
the credit commensurate with the extent of their participation in the
activity.
Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education
activity is 0.5 contact hour(s).
American Board of Internal Medicine Maintenance of
Certification
Successful
completion of this CME activity, which includes participation in the
evaluation component, enables the participant to earn up to 0.5 medical
knowledge MOC point(s) in the American Board of Internal Medicine’s (ABIM)
Maintenance of Certification (MOC) program. Participants will earn MOC points
equivalent to the amount of CME credits claimed for the activity. It is the
CME activity provider’s responsibility to submit participant completion
information to ACCME for the purpose of granting ABIM MOC credit.
Interprofessional Continuing
Education
This
activity was planned by and for the healthcare team, and learners will
receive 0.5 Interprofessional Continuing Education (IPCE) credit for learning
and change.
Instructions for Receiving Credit
In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 75% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at contact@rmei.com.
Users must:
- Read the learning objectives and faculty disclosures
- Participate in the activity
- Complete the activity evaluation and attest to credit
Physicians claiming ABIM MOC points must provide ABIM ID and month/date of birth and score 75% or higher on the post-test.
For Physicians: MOC points will be submitted to ABIM profiles within 4 weeks of completion.
There is no fee for this educational activity.
Your Feedback is Important!
COMPLETE THE EVALUATION FORM
AND YOU WILL BE ENTERED INTO A DRAWING FOR A $100* AMAZON GIFT
CARD!
*The expense for this gift card is solely funded by RMEI Medical Education,
LLC.
No supporter funding was used for the expense of this gift card.
Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly
accredited provider. The winner will be selected via automated random drawing
on a quarterly basis from among all eligible entries and notified through the
contact information provided. In accordance with our privacy policy, we do
not share your information with any third parties. By entering the
sweepstakes, you grant RMEI permission to use your e-mail address to reach
you for notification and prize fulfillment. Only individuals who complete the
evaluation forms and provide contact information will be eligible to win.
Open to those who have a US postal address and who are 18 years or older.
Only one prize per person and per household will be awarded. The prize will
be a $100 Amazon gift card.
Statement of Commercial Support
This activity is supported by an educational grant from Genentech, a member of the Roche Group.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Activity Details
0.5 ANCC Contact Hour(s)
0.5 IPCE Credit(s)™
0.5 ABIM MOC Point(s)
Expires: February 10, 2023
Provided By
RMEI Medical Education, LLC
Target Audience
This activity is intended for emergency medicine, hospital medicine, infectious disease, internal medicine, and pediatric clinicians (MD/NP/PA/Nurses) involved in the treatment of patients with severe COVID-19 infection.
Learning Objectives
Upon completion of this activity, participants should be better able to:
- Assess disease severity and implications in patients with COVID-19
- Incorporate emergency use authorization status and available clinical trial data into the selection of treatment for patients hospitalized with COVID-19
- Integrate the unique roles and responsibilities of interprofessional care team members in the management of severe COVID-19 in hospitalized patients
Activity Description
“I was dying … and I was dying alone,” says Nancy, recalling her lonely isolation in the intensive care unit as one of the earlier victims of COVID-19 in her region. This dynamic panel features an interprofessional lineup of experts who will debate and discuss data, guidelines, and literature on the treatment of severe COVID-19 in the hospital setting and what it all means for your practice and patients. Additionally, they are joined by Nancy who survived the earliest days of COVID-19 in the United States and will share her learning moments with the panel and learners.
Chair
Director, Clinical Infectious Diseases Research and MultiSpecialties
Clinical Associate Professor, Medicine (Tulane University)
Associate Professor, University of Queensland/Ochsner Clinical School, Brisbane, Australia
Ochsner Health
New Orleans, LA
Faculty
Chief, Division of Infectious Diseases
Vice-Chair, Faculty Development
Professor, Medicine
Director, San Antonio Center for Medical Mycology
UT Health San Antonio
San Antonio, TX
Advanced Practice Provider, Pulmonary Critical Care
Chairperson, System Critical Care Integration Council
Ochsner Medical Center
Ochsner Health
New Orleans, LA
Disclosure of Financial Relationships
RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy.
Faculty
Julia B. García-Díaz, MD, MSc, FACP, FIDSA, CPI, has no relevant
financial relationships with ineligible companies to disclose.
Thomas F. Patterson, MD, FACP, FIDSA, has relevant financial relationships with Appili, Basilea, Gilead, Mayne, Merck, Pfizer, Scynexis, Sfunga (Consultant); Cidara, F2G (Researcher).
Fiona A. Winterbottom, DNP, MSN, APRN, ACNS-BC, ACHPN, CCRN, has relevant financial relationships with Baxter (Advisor); Zoll (Speaker/Speaker’s Bureau).
Patient participating in this activity has no relevant financial relationship(s) with ineligible companies to disclose.
All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.
Planners and Managers
RMEI Medical Education, LLC planners and managers have no relevant financial
relationship(s) with ineligible companies to disclose.
Joint Accreditation Statement
In support
of improving patient care, RMEI Medical Education, LLC is jointly accredited
by the Accreditation Council for Continuing Medical Education (ACCME), the
Accreditation Council for Pharmacy Education (ACPE), and the American Nurses
Credentialing Center (ANCC), to provide continuing education for the
healthcare team.
Designation of Credit
Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum
of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only
the credit commensurate with the extent of their participation in the
activity.
Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education
activity is 0.5 contact hour(s).
American Board of Internal Medicine Maintenance of
Certification
Successful
completion of this CME activity, which includes participation in the
evaluation component, enables the participant to earn up to 0.5 medical
knowledge MOC point(s) in the American Board of Internal Medicine’s (ABIM)
Maintenance of Certification (MOC) program. Participants will earn MOC points
equivalent to the amount of CME credits claimed for the activity. It is the
CME activity provider’s responsibility to submit participant completion
information to ACCME for the purpose of granting ABIM MOC credit.
Interprofessional Continuing
Education
This
activity was planned by and for the healthcare team, and learners will
receive 0.5 Interprofessional Continuing Education (IPCE) credit for learning
and change.
Instructions for Receiving Credit
In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 75% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at contact@rmei.com.
Users must:
- Read the learning objectives and faculty disclosures
- Participate in the activity
- Complete the activity evaluation and attest to credit
Physicians claiming ABIM MOC points must provide ABIM ID and month/date of birth and score 75% or higher on the post-test.
For Physicians: MOC points will be submitted to ABIM profiles within 4 weeks of completion.
There is no fee for this educational activity.
Your Feedback is Important!
COMPLETE THE EVALUATION FORM
AND YOU WILL BE ENTERED INTO A DRAWING FOR A $100* AMAZON GIFT
CARD!
*The expense for this gift card is solely funded by RMEI Medical Education,
LLC.
No supporter funding was used for the expense of this gift card.
Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly
accredited provider. The winner will be selected via automated random drawing
on a quarterly basis from among all eligible entries and notified through the
contact information provided. In accordance with our privacy policy, we do
not share your information with any third parties. By entering the
sweepstakes, you grant RMEI permission to use your e-mail address to reach
you for notification and prize fulfillment. Only individuals who complete the
evaluation forms and provide contact information will be eligible to win.
Open to those who have a US postal address and who are 18 years or older.
Only one prize per person and per household will be awarded. The prize will
be a $100 Amazon gift card.
Statement of Commercial Support
This activity is supported by an educational grant from Genentech, a member of the Roche Group.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Pulmonary/Respiratory Medicine Presentations
Understanding the Immunopathology of COVID-19 Progression to Make More Informed Treatment Decisions
StartActivity Details
Expires: April 27, 2023
Updates to COVID-19 information as it pertains to the content presented within this activity will be updated on a quarterly basis from program launch until program expiration. Please save this link for further education!
Accredited By
This continuing medical education activity is provided by
Target Audience
The intended audience for this activity is pulmonologists, hospitalists, critical care physicians, intensivists, immunologists, infectious disease specialists, rheumatologists, and other health care professionals involved in the management of patients hospitalized with COVID-19.
Learning Objectives
Upon successful completion of this activity, participants should be better able to:
- Outline the role of the innate and adaptive immune response throughout the progression of COVID-19.
- Determine optimal management for patients hospitalized with COVID-19 based on the latest recommendations and clinical evidence regarding the use of immunomodulatory agents.
- Describe how variables such as disease severity, timing, and comorbidities should impact clinical decision-making for patients hospitalized with COVID-19.
Activity Description
Severe COVID-19 is characterized by a hyperinflammatory state and significant pulmonary disease that can result in respiratory failure and organ damage. Immunomodulatory therapies such as Janus kinase inhibitors and interleukin-6 inhibitors can reduce the risk of disease progression and death in hospitalized patients with COVID-19. In this CME activity, faculty review the clinical and immunologic events underlying COVID-19; appraise the latest data on immunomodulatory therapies; and discuss how disease severity, timing, and comorbidities should impact clinical decision-making for patients hospitalized with COVID-19. Clinical cases will be discussed to highlight key educational objectives and strategies for patient management.
Statement of Educational Need
The COVID-19 pandemic has led to a health care crisis with widespread global morbidity and mortality, spurring unprecedented levels of ongoing research for effective therapeutic strategies. A major challenge for clinicians involved in patient management is staying current on the latest evidence-based care despite the rapid influx of data, drug shortages, and evolving treatment guidelines. This program provides updates on developments and data on the immunopathology and management of COVID-19.
Agenda
Introduction
Leonard H. Calabrese, DO
Immunological Mechanisms Underlying COVID-19
Progression
Leonard H. Calabrese, DO
Advances in the Use of Immunomodulatory Agents for Patients
Hospitalized With COVID-19
Andre Kalil, MD, MPH
Clinical Cases: Management of COVID-19 in the Inpatient
Setting
Susan E. Kline, MD, MPH
Panel Discussion
Leonard H. Calabrese, DO; Andre Kalil, MD, MPH
Activity Chair
Professor of Medicine
Cleveland Clinic Lerner College of Medicine
Case Western Reserve University
R.J. Fasenmyer Chair of Clinical Immunology
Cleveland Clinic
Cleveland, OH
Relevant Disclosures:
Consultant: AbbVie, Bristol-Myers Squibb, Genentech, Gilead, GlaxoSmithKline, Lilly, Pfizer, Regeneron
Speaker Contracted by Ineligible Company: AbbVie, AstraZeneca, GlaxoSmithKline
Faculty
Professor of Medicine
Director, Transplant Infectious Diseases
University of Nebraska Medical Center
Omaha, NE
Relevant Disclosures:
No relevant financial relationships to disclose.
Professor of Medicine
Director, Division of Infectious Diseases and International Medicine
Department of Medicine
University of Minnesota Medical School
Minneapolis, MN
Relevant Disclosures:
No relevant financial relationships to disclose.
Reviewer
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Relevant Disclosures:
No relevant financial relationships to disclose.
Conflict of Interest Policy/Disclosure Statement
Vindico Medical Education adheres to the Accreditation Council for Continuing Medical Education’s (ACCME) Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a continuing education activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Relationship information is accurate at the time of content development.
Vindico Medical Education Staff:
No relevant financial relationships to disclose.
Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.
Accreditation Statement
Vindico Medical Education is accredited by the ACCME to provide continuing medical education for physicians.
Designation of Credit
Vindico Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Instructions for Receiving Credit
To participate in this CME activity, you must read the objectives, answer the polling and pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 75% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ certificate.
Statement of Commercial Support
This activity is supported by an educational grant from Lilly.
Unlabeled and Investigational Usage
The audience is advised that this continuing education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)–approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage.
Disclaimer
The material presented at or in any Vindico Medical Education continuing education activity does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the FDA. All readers and continuing education participants should verify all information before treating patients or utilizing any product.
Notice
Faculty, topics, program schedule, and credit hours are subject to change. Recording of any manner is prohibited without written permission from Vindico Medical Education, Office of Medical Affairs and Compliance.
CME Questions?
Contact us at cme@vindicoCME.com
Activity Details
Expires: April 27, 2023
Updates to COVID-19 information as it pertains to the content presented within this activity will be updated on a quarterly basis from program launch until program expiration. Please save this link for further education!
Accredited By
This continuing medical education activity is provided by
Target Audience
The intended audience for this activity is pulmonologists, hospitalists, critical care physicians, intensivists, immunologists, infectious disease specialists, rheumatologists, and other health care professionals involved in the management of patients hospitalized with COVID-19.
Learning Objectives
Upon successful completion of this activity, participants should be better able to:
- Outline the role of the innate and adaptive immune response throughout the progression of COVID-19.
- Determine optimal management for patients hospitalized with COVID-19 based on the latest recommendations and clinical evidence regarding the use of immunomodulatory agents.
- Describe how variables such as disease severity, timing, and comorbidities should impact clinical decision-making for patients hospitalized with COVID-19.
Activity Description
Severe COVID-19 is characterized by a hyperinflammatory state and significant pulmonary disease that can result in respiratory failure and organ damage. Immunomodulatory therapies such as Janus kinase inhibitors and interleukin-6 inhibitors can reduce the risk of disease progression and death in hospitalized patients with COVID-19. In this CME activity, faculty review the clinical and immunologic events underlying COVID-19; appraise the latest data on immunomodulatory therapies; and discuss how disease severity, timing, and comorbidities should impact clinical decision-making for patients hospitalized with COVID-19. Clinical cases will be discussed to highlight key educational objectives and strategies for patient management.
Statement of Educational Need
The COVID-19 pandemic has led to a health care crisis with widespread global morbidity and mortality, spurring unprecedented levels of ongoing research for effective therapeutic strategies. A major challenge for clinicians involved in patient management is staying current on the latest evidence-based care despite the rapid influx of data, drug shortages, and evolving treatment guidelines. This program provides updates on developments and data on the immunopathology and management of COVID-19.
Agenda
Introduction
Leonard H. Calabrese, DO
Immunological Mechanisms Underlying COVID-19
Progression
Leonard H. Calabrese, DO
Advances in the Use of Immunomodulatory Agents for Patients
Hospitalized With COVID-19
Andre Kalil, MD, MPH
Clinical Cases: Management of COVID-19 in the Inpatient
Setting
Susan E. Kline, MD, MPH
Panel Discussion
Leonard H. Calabrese, DO; Andre Kalil, MD, MPH
Activity Chair
Professor of Medicine
Cleveland Clinic Lerner College of Medicine
Case Western Reserve University
R.J. Fasenmyer Chair of Clinical Immunology
Cleveland Clinic
Cleveland, OH
Relevant Disclosures:
Consultant: AbbVie, Bristol-Myers Squibb, Genentech, Gilead, GlaxoSmithKline, Lilly, Pfizer, Regeneron
Speaker Contracted by Ineligible Company: AbbVie, AstraZeneca, GlaxoSmithKline
Faculty
Professor of Medicine
Director, Transplant Infectious Diseases
University of Nebraska Medical Center
Omaha, NE
Relevant Disclosures:
No relevant financial relationships to disclose.
Professor of Medicine
Director, Division of Infectious Diseases and International Medicine
Department of Medicine
University of Minnesota Medical School
Minneapolis, MN
Relevant Disclosures:
No relevant financial relationships to disclose.
Reviewer
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Relevant Disclosures:
No relevant financial relationships to disclose.
Conflict of Interest Policy/Disclosure Statement
Vindico Medical Education adheres to the Accreditation Council for Continuing Medical Education’s (ACCME) Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a continuing education activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Relationship information is accurate at the time of content development.
Vindico Medical Education Staff:
No relevant financial relationships to disclose.
Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.
Accreditation Statement
Vindico Medical Education is accredited by the ACCME to provide continuing medical education for physicians.
Designation of Credit
Vindico Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Instructions for Receiving Credit
To participate in this CME activity, you must read the objectives, answer the polling and pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 75% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ certificate.
Statement of Commercial Support
This activity is supported by an educational grant from Lilly.
Unlabeled and Investigational Usage
The audience is advised that this continuing education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)–approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage.
Disclaimer
The material presented at or in any Vindico Medical Education continuing education activity does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the FDA. All readers and continuing education participants should verify all information before treating patients or utilizing any product.
Notice
Faculty, topics, program schedule, and credit hours are subject to change. Recording of any manner is prohibited without written permission from Vindico Medical Education, Office of Medical Affairs and Compliance.
CME Questions?
Contact us at cme@vindicoCME.com
Optimizing Frontline Immunotherapy in Advanced Non-Small Cell Lung Cancer: Program Highlights
StartActivity Details
Expires: April 7, 2023
Provided By
RMEI Medical Education, LLC
Target Audience
This activity is intended for oncology, pathology, and pulmonology clinicians (MD/DO/NP/PA) engaged in the care of patients with non-small cell lung cancer (NSCLC).
Learning Objectives
Upon completion of this activity, participants should be better able to:
- Identify patients with advanced non-small cell lung cancer (NSCLC) eligible for frontline immunotherapy using biomarker test results
- Apply efficacy and safety data on frontline immunotherapy when treating patients with advanced NSCLC
Activity Description
This continuing medical education (CME) activity will provide highlights from 2 Live Grand Round Sessions, offering expert insights on key concepts in immunotherapy for advanced NSCLC. Core topics include the rationale for immunotherapy, the critical importance of guideline-driven biomarker testing in patient selection, and the most current data on checkpoint inhibitor monotherapies, combinations, and emerging regimens.
Faculty
Deputy Chief, Molecular Diagnostics Service
Medical Director, Molecular Hematopathology
Memorial Sloan Kettering Cancer Center
New York, NY
Professor, Medicine
Lineberger Comprehensive Cancer Center
The University of North Carolina at Chapel Hill
Chapel Hill, NC
Content Reviewer
Assistant Attending, Molecular and Thoracic Pathology
Memorial Sloan Kettering Cancer Center
New York, NY
Disclosure of Financial Relationships
RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy.
Faculty
Maria E. Arcila, MD, has relevant financial relationships with AstraZeneca, Bristol-Myers Squibb, Invivoscribe, Janssen Global Services, Merck, Roche (Consultant); Biocartis, Invivoscribe (Speaker/Speaker’s Bureau).
Jason M. Chang, MD, has no relevant financial relationship(s) with ineligible companies to disclose.
Jared M. Weiss, MD, has relevant financial relationships with Achilles, En Fuego (convertible note), Lyell, Nuvalent, Vesselon (warrants) (Stock/Shareholder); AbbVie, AstraZeneca, Azitra, Blueprint, Boehringer Ingelheim, Eli Lilly, EMD Serono, G1, Genentech, Genmab, Jazz Pharmaceuticals, Jounce, Nanobiotix, Pfizer, Regeneron, Saatchi, Sumitomo Dainippon Pharma Oncology (Consultant); Amgen, AstraZeneca, Boehringer Ingelheim, G1, Immunicum, Loxo/Lilly, Merck, Mirati, PDS Biotech, Sumitomo Dainippon Pharma Oncology (Grant/Research Support).
All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.
Planners and Managers
RMEI Medical Education, LLC planners and managers have no relevant financial
relationship(s) with ineligible companies to disclose.
Joint Accreditation Statement
In support
of improving patient care, RMEI Medical Education, LLC is jointly accredited
by the Accreditation Council for Continuing Medical Education (ACCME), the
Accreditation Council for Pharmacy Education (ACPE), and the American Nurses
Credentialing Center (ANCC) to provide continuing education for the
healthcare team.
Designation of Credit
Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum
of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only
the credit commensurate with the extent of their participation in the
activity.
Instructions for Receiving Credit
In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 83% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at contact@rmei.com.
Users must:
- Read the learning objectives and faculty disclosures
- Participate in the activity
- Complete the activity evaluation and attest to credit
There is no fee for this educational activity.
Your Feedback is Important!
COMPLETE THE EVALUATION FORM
AND YOU WILL BE ENTERED INTO A DRAWING
FOR A $100* AMAZON GIFT CARD!
*The expense for this gift card is solely funded by RMEI Medical Education,
LLC.
No supporter funding was used for the expense of this gift card.
Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly
accredited provider. The winner will be selected via automated random drawing
on a quarterly basis from among all eligible entries and notified through the
contact information provided. In accordance with our privacy policy, we do
not share your information with any third parties. By entering the
sweepstakes, you grant RMEI permission to use your e-mail address to reach
you for notification and prize fulfillment. Only individuals who complete the
evaluation forms and provide contact information will be eligible to win.
Open to those who have a US postal address and who are 18 years or older.
Only one prize per person and per household will be awarded. The prize will
be a $100 Amazon gift card.
Statement of Commercial Support
This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc and Sanofi Genzyme.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
Activity Details
Expires: April 7, 2023
Provided By
RMEI Medical Education, LLC
Target Audience
This activity is intended for oncology, pathology, and pulmonology clinicians (MD/DO/NP/PA) engaged in the care of patients with non-small cell lung cancer (NSCLC).
Learning Objectives
Upon completion of this activity, participants should be better able to:
- Identify patients with advanced non-small cell lung cancer (NSCLC) eligible for frontline immunotherapy using biomarker test results
- Apply efficacy and safety data on frontline immunotherapy when treating patients with advanced NSCLC
Activity Description
This continuing medical education (CME) activity will provide highlights from 2 Live Grand Round Sessions, offering expert insights on key concepts in immunotherapy for advanced NSCLC. Core topics include the rationale for immunotherapy, the critical importance of guideline-driven biomarker testing in patient selection, and the most current data on checkpoint inhibitor monotherapies, combinations, and emerging regimens.
Faculty
Deputy Chief, Molecular Diagnostics Service
Medical Director, Molecular Hematopathology
Memorial Sloan Kettering Cancer Center
New York, NY
Professor, Medicine
Lineberger Comprehensive Cancer Center
The University of North Carolina at Chapel Hill
Chapel Hill, NC
Content Reviewer
Assistant Attending, Molecular and Thoracic Pathology
Memorial Sloan Kettering Cancer Center
New York, NY
Disclosure of Financial Relationships
RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy.
Faculty
Maria E. Arcila, MD, has relevant financial relationships with AstraZeneca, Bristol-Myers Squibb, Invivoscribe, Janssen Global Services, Merck, Roche (Consultant); Biocartis, Invivoscribe (Speaker/Speaker’s Bureau).
Jason M. Chang, MD, has no relevant financial relationship(s) with ineligible companies to disclose.
Jared M. Weiss, MD, has relevant financial relationships with Achilles, En Fuego (convertible note), Lyell, Nuvalent, Vesselon (warrants) (Stock/Shareholder); AbbVie, AstraZeneca, Azitra, Blueprint, Boehringer Ingelheim, Eli Lilly, EMD Serono, G1, Genentech, Genmab, Jazz Pharmaceuticals, Jounce, Nanobiotix, Pfizer, Regeneron, Saatchi, Sumitomo Dainippon Pharma Oncology (Consultant); Amgen, AstraZeneca, Boehringer Ingelheim, G1, Immunicum, Loxo/Lilly, Merck, Mirati, PDS Biotech, Sumitomo Dainippon Pharma Oncology (Grant/Research Support).
All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.
Planners and Managers
RMEI Medical Education, LLC planners and managers have no relevant financial
relationship(s) with ineligible companies to disclose.
Joint Accreditation Statement
In support
of improving patient care, RMEI Medical Education, LLC is jointly accredited
by the Accreditation Council for Continuing Medical Education (ACCME), the
Accreditation Council for Pharmacy Education (ACPE), and the American Nurses
Credentialing Center (ANCC) to provide continuing education for the
healthcare team.
Designation of Credit
Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum
of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only
the credit commensurate with the extent of their participation in the
activity.
Instructions for Receiving Credit
In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 83% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at contact@rmei.com.
Users must:
- Read the learning objectives and faculty disclosures
- Participate in the activity
- Complete the activity evaluation and attest to credit
There is no fee for this educational activity.
Your Feedback is Important!
COMPLETE THE EVALUATION FORM
AND YOU WILL BE ENTERED INTO A DRAWING
FOR A $100* AMAZON GIFT CARD!
*The expense for this gift card is solely funded by RMEI Medical Education,
LLC.
No supporter funding was used for the expense of this gift card.
Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly
accredited provider. The winner will be selected via automated random drawing
on a quarterly basis from among all eligible entries and notified through the
contact information provided. In accordance with our privacy policy, we do
not share your information with any third parties. By entering the
sweepstakes, you grant RMEI permission to use your e-mail address to reach
you for notification and prize fulfillment. Only individuals who complete the
evaluation forms and provide contact information will be eligible to win.
Open to those who have a US postal address and who are 18 years or older.
Only one prize per person and per household will be awarded. The prize will
be a $100 Amazon gift card.
Statement of Commercial Support
This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc and Sanofi Genzyme.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
Case Conundrums in COVID-19: Primer on the Immune Basis of COVID-19 Progression
StartExpires: March 29, 2023
Accredited By
This continuing medical education activity is provided by
Target Audience
The intended audience for this activity is rheumatologists, hospitalists, critical care physicians, intensivists, immunologists, infectious disease specialists, pulmonologists, and other health care professionals involved in the management of patients hospitalized with COVID-19.
Learning Objectives
Upon successful completion of the activity, participants should be better able to:
- Describe the role of the innate and adaptive immune response underlying the progression of COVID-19 from early-stage disease to hospitalization to hyperinflammation.
Activity Description
In this 4-part Curbside Consults video series, experts from infectious disease, pulmonology, and rheumatology will review clinical cases across the spectrum of COVID-19 disease. Strategies will be discussed for the prevention and management of severe COVID-19–associated hyperinflammation and respiratory damage.
Statement of Educational Need
The COVID-19 pandemic has led to an unprecedented health care crisis with widespread global morbidity and mortality. Severe COVID-19 is characterized by a hyperinflammatory state and significant pulmonary disease that can result in respiratory failure and organ damage. Targeted immunomodulatory treatments can reduce the risk of disease progression and death in hospitalized patients with COVID-19. Recent advances have spurred unprecedented levels of ongoing clinical research, creating a substantial challenge for clinicians to stay up to date on the latest evidence-based care and rapidly evolving treatment guidelines.
Faculty
Leonard H. Calabrese, DO
Professor of Medicine
Cleveland Clinic Lerner College of Medicine
Case Western Reserve University
R.J. Fasenmyer Chair of Clinical Immunology
Cleveland Clinic
Cleveland, OH
Relevant Financial Disclosure:
Consultant: AbbVie, Bristol-Myers Squibb, Genentech, Gilead, GlaxoSmithKline, Lilly, Pfizer, Regeneron
Speaker Contracted by Ineligible Company: AbbVie, AstraZeneca, GlaxoSmithKline
Randy Q. Cron, MD, PhD
Professor of Pediatrics
Arthritis Foundation, Alabama Chapter Endowed Chair in Pediatric Rheumatology
University of Alabama at Birmingham Heersink School of Medicine
Birmingham, AL
Relevant Financial Disclosure:
Advisor: Sobi
Consultant: Sironax, Sobi
Speaker Contracted by Ineligible Company: Sobi
Independent Research Contractor: Sobi
Adjudication Committee Chair: Pfizer
Reviewer
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.
Vindico Medical Education Staff
Disclosure: No relevant financial relationships to disclose.
Signed Disclosures are on file at Vindico Medical Education, Office
of Medical Affairs and Compliance.
Conflict of Interest Policy/Disclosure Statement
Vindico Medical Education adheres to the Accreditation Council for Continuing Medical Education’s (ACCME) Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers, or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Accreditation Statement
Vindico Medical Education is accredited by the ACCME to provide continuing medical education for physicians.
Designation of Credit
Vindico Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Instructions for Receiving Credit
To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 100% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.
Statement of Commercial Support
This activity is supported by an educational grant from Lilly.
Disclaimer Statement/Disclosure of Unlabeled Use
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)–approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.
Copyright Statement
Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2022 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.
CME Questions?
Contact us at CME@VindicoCME.com
Expires: March 29, 2023
Accredited By
This continuing medical education activity is provided by
Target Audience
The intended audience for this activity is rheumatologists, hospitalists, critical care physicians, intensivists, immunologists, infectious disease specialists, pulmonologists, and other health care professionals involved in the management of patients hospitalized with COVID-19.
Learning Objectives
Upon successful completion of the activity, participants should be better able to:
- Describe the role of the innate and adaptive immune response underlying the progression of COVID-19 from early-stage disease to hospitalization to hyperinflammation.
Activity Description
In this 4-part Curbside Consults video series, experts from infectious disease, pulmonology, and rheumatology will review clinical cases across the spectrum of COVID-19 disease. Strategies will be discussed for the prevention and management of severe COVID-19–associated hyperinflammation and respiratory damage.
Statement of Educational Need
The COVID-19 pandemic has led to an unprecedented health care crisis with widespread global morbidity and mortality. Severe COVID-19 is characterized by a hyperinflammatory state and significant pulmonary disease that can result in respiratory failure and organ damage. Targeted immunomodulatory treatments can reduce the risk of disease progression and death in hospitalized patients with COVID-19. Recent advances have spurred unprecedented levels of ongoing clinical research, creating a substantial challenge for clinicians to stay up to date on the latest evidence-based care and rapidly evolving treatment guidelines.
Faculty
Leonard H. Calabrese, DO
Professor of Medicine
Cleveland Clinic Lerner College of Medicine
Case Western Reserve University
R.J. Fasenmyer Chair of Clinical Immunology
Cleveland Clinic
Cleveland, OH
Relevant Financial Disclosure:
Consultant: AbbVie, Bristol-Myers Squibb, Genentech, Gilead, GlaxoSmithKline, Lilly, Pfizer, Regeneron
Speaker Contracted by Ineligible Company: AbbVie, AstraZeneca, GlaxoSmithKline
Randy Q. Cron, MD, PhD
Professor of Pediatrics
Arthritis Foundation, Alabama Chapter Endowed Chair in Pediatric Rheumatology
University of Alabama at Birmingham Heersink School of Medicine
Birmingham, AL
Relevant Financial Disclosure:
Advisor: Sobi
Consultant: Sironax, Sobi
Speaker Contracted by Ineligible Company: Sobi
Independent Research Contractor: Sobi
Adjudication Committee Chair: Pfizer
Reviewer
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.
Vindico Medical Education Staff
Disclosure: No relevant financial relationships to disclose.
Signed Disclosures are on file at Vindico Medical Education, Office
of Medical Affairs and Compliance.
Conflict of Interest Policy/Disclosure Statement
Vindico Medical Education adheres to the Accreditation Council for Continuing Medical Education’s (ACCME) Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers, or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Accreditation Statement
Vindico Medical Education is accredited by the ACCME to provide continuing medical education for physicians.
Designation of Credit
Vindico Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Instructions for Receiving Credit
To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 100% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.
Statement of Commercial Support
This activity is supported by an educational grant from Lilly.
Disclaimer Statement/Disclosure of Unlabeled Use
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)–approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.
Copyright Statement
Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2022 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.
CME Questions?
Contact us at CME@VindicoCME.com
Case Conundrums in COVID-19: A Patient Presenting to the ED With Mild COVID-19
StartActivity Details
Expires: March 29, 2023
Accredited By
This continuing medical education activity is provided by
Target Audience
The intended audience for this activity is rheumatologists, hospitalists, critical care physicians, intensivists, immunologists, infectious disease specialists, pulmonologists, and other health care professionals involved in the management of patients hospitalized with COVID-19.
Learning Objectives
Upon successful completion of the activity, participants should be better able to:
- Evaluate the latest data regarding immune-based therapies, including glucocorticoids, JAK inhibitors, and other targeted therapies for the management of patients with COVID-19.
- Recognize how variables such as disease severity, comorbidities, and immunologic endotypes may impact the management of patients with COVID-19.
Activity Description
In this 4-part Curbside Consults video series, experts from infectious disease, pulmonology, and rheumatology will review clinical cases across the spectrum of COVID-19 disease. Strategies will be discussed for the prevention and management of severe COVID-19–associated hyperinflammation and respiratory damage.
Statement of Educational Need
The COVID-19 pandemic has led to an unprecedented health care crisis with widespread global morbidity and mortality. Severe COVID-19 is characterized by a hyperinflammatory state and significant pulmonary disease that can result in respiratory failure and organ damage. Targeted immunomodulatory treatments can reduce the risk of disease progression and death in hospitalized patients with COVID-19. Recent advances have spurred unprecedented levels of ongoing clinical research, creating a substantial challenge for clinicians to stay up to date on the latest evidence-based care and rapidly evolving treatment guidelines.
Faculty
Leonard H. Calabrese, DO
Professor of Medicine
Cleveland Clinic Lerner College of Medicine
Case Western Reserve University
R.J. Fasenmyer Chair of Clinical Immunology
Cleveland Clinic
Cleveland, OH
Relevant Financial Disclosure:
Consultant: AbbVie, Bristol-Myers Squibb, Genentech, Gilead, GlaxoSmithKline, Lilly, Pfizer, Regeneron
Speaker Contracted by Ineligible Company: AbbVie, AstraZeneca, GlaxoSmithKline
Phyllis C. Tien, MD
Associate Professor of Medicine
University of California, San Francisco
San Francisco VA Medical Center, Infectious Disease Section
San Francisco, CA
Relevant Financial Disclosure:
Independent Research Contractor (paid to institution): Gilead, Lilly, Merck
Reviewer
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.
Vindico Medical Education Staff
Disclosure: No relevant financial relationships to disclose.
Signed Disclosures are on file at Vindico Medical Education, Office
of Medical Affairs and Compliance.
Conflict of Interest Policy/Disclosure Statement
Vindico Medical Education adheres to the Accreditation Council for Continuing Medical Education’s (ACCME) Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers, or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Accreditation Statement
Vindico Medical Education is accredited by the ACCME to provide continuing medical education for physicians.
Designation of Credit
Vindico Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Instructions for Receiving Credit
To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 100% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.
Statement of Commercial Support
This activity is supported by an educational grant from Lilly.
Disclaimer Statement/Disclosure of Unlabeled Use
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)–approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.
Copyright Statement
Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2022 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.
CME Questions?
Contact us at CME@VindicoCME.com
Activity Details
Expires: March 29, 2023
Accredited By
This continuing medical education activity is provided by
Target Audience
The intended audience for this activity is rheumatologists, hospitalists, critical care physicians, intensivists, immunologists, infectious disease specialists, pulmonologists, and other health care professionals involved in the management of patients hospitalized with COVID-19.
Learning Objectives
Upon successful completion of the activity, participants should be better able to:
- Evaluate the latest data regarding immune-based therapies, including glucocorticoids, JAK inhibitors, and other targeted therapies for the management of patients with COVID-19.
- Recognize how variables such as disease severity, comorbidities, and immunologic endotypes may impact the management of patients with COVID-19.
Activity Description
In this 4-part Curbside Consults video series, experts from infectious disease, pulmonology, and rheumatology will review clinical cases across the spectrum of COVID-19 disease. Strategies will be discussed for the prevention and management of severe COVID-19–associated hyperinflammation and respiratory damage.
Statement of Educational Need
The COVID-19 pandemic has led to an unprecedented health care crisis with widespread global morbidity and mortality. Severe COVID-19 is characterized by a hyperinflammatory state and significant pulmonary disease that can result in respiratory failure and organ damage. Targeted immunomodulatory treatments can reduce the risk of disease progression and death in hospitalized patients with COVID-19. Recent advances have spurred unprecedented levels of ongoing clinical research, creating a substantial challenge for clinicians to stay up to date on the latest evidence-based care and rapidly evolving treatment guidelines.
Faculty
Leonard H. Calabrese, DO
Professor of Medicine
Cleveland Clinic Lerner College of Medicine
Case Western Reserve University
R.J. Fasenmyer Chair of Clinical Immunology
Cleveland Clinic
Cleveland, OH
Relevant Financial Disclosure:
Consultant: AbbVie, Bristol-Myers Squibb, Genentech, Gilead, GlaxoSmithKline, Lilly, Pfizer, Regeneron
Speaker Contracted by Ineligible Company: AbbVie, AstraZeneca, GlaxoSmithKline
Phyllis C. Tien, MD
Associate Professor of Medicine
University of California, San Francisco
San Francisco VA Medical Center, Infectious Disease Section
San Francisco, CA
Relevant Financial Disclosure:
Independent Research Contractor (paid to institution): Gilead, Lilly, Merck
Reviewer
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.
Vindico Medical Education Staff
Disclosure: No relevant financial relationships to disclose.
Signed Disclosures are on file at Vindico Medical Education, Office
of Medical Affairs and Compliance.
Conflict of Interest Policy/Disclosure Statement
Vindico Medical Education adheres to the Accreditation Council for Continuing Medical Education’s (ACCME) Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers, or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Accreditation Statement
Vindico Medical Education is accredited by the ACCME to provide continuing medical education for physicians.
Designation of Credit
Vindico Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Instructions for Receiving Credit
To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 100% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.
Statement of Commercial Support
This activity is supported by an educational grant from Lilly.
Disclaimer Statement/Disclosure of Unlabeled Use
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)–approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.
Copyright Statement
Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2022 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.
CME Questions?
Contact us at CME@VindicoCME.com
Case Conundrums in COVID-19: A Newly Admitted Patient With COVID-19 and Worsening Respiratory Symptoms
StartExpires: March 29, 2023
Accredited By
This continuing medical education activity is provided by
Target Audience
The intended audience for this activity is rheumatologists, hospitalists, critical care physicians, intensivists, immunologists, infectious disease specialists, pulmonologists, and other health care professionals involved in the management of patients hospitalized with COVID-19.
Learning Objectives
Upon successful completion of the activity, participants should be better able to:
- Evaluate the latest data regarding immune-based therapies, including glucocorticoids, JAK inhibitors, and other targeted therapies for the management of patients with COVID-19.
- Recognize how variables such as disease severity, comorbidities, and immunologic endotypes may impact the management of patients with COVID-19.
Activity Description
In this 4-part Curbside Consults video series, experts from infectious disease, pulmonology, and rheumatology will review clinical cases across the spectrum of COVID-19 disease. Strategies will be discussed for the prevention and management of severe COVID-19–associated hyperinflammation and respiratory damage.
Statement of Educational Need
The COVID-19 pandemic has led to an unprecedented health care crisis with widespread global morbidity and mortality. Severe COVID-19 is characterized by a hyperinflammatory state and significant pulmonary disease that can result in respiratory failure and organ damage. Targeted immunomodulatory treatments can reduce the risk of disease progression and death in hospitalized patients with COVID-19. Recent advances have spurred unprecedented levels of ongoing clinical research, creating a substantial challenge for clinicians to stay up to date on the latest evidence-based care and rapidly evolving treatment guidelines.
Faculty
Leonard H. Calabrese, DO
Professor of Medicine
Cleveland Clinic Lerner College of Medicine
Case Western Reserve University
R.J. Fasenmyer Chair of Clinical Immunology
Cleveland Clinic
Cleveland, OH
Relevant Financial Disclosure:
Consultant: AbbVie, Bristol-Myers Squibb, Genentech, Gilead, GlaxoSmithKline, Lilly, Pfizer, Regeneron
Speaker Contracted by Ineligible Company: AbbVie, AstraZeneca, GlaxoSmithKline
Phyllis C. Tien, MD
Associate Professor of Medicine
University of California, San Francisco
San Francisco VA Medical Center, Infectious Disease Section
San Francisco, CA
Relevant Financial Disclosure:
Independent Research Contractor (paid to institution): Gilead, Lilly, Merck
Reviewer
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.
Vindico Medical Education Staff
Disclosure: No relevant financial relationships to disclose.
Signed Disclosures are on file at Vindico Medical Education, Office
of Medical Affairs and Compliance.
Conflict of Interest Policy/Disclosure Statement
Vindico Medical Education adheres to the Accreditation Council for Continuing Medical Education’s (ACCME) Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers, or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Accreditation Statement
Vindico Medical Education is accredited by the ACCME to provide continuing medical education for physicians.
Designation of Credit
Vindico Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Instructions for Receiving Credit
To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 100% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.
Statement of Commercial Support
This activity is supported by an educational grant from Lilly.
Disclaimer Statement/Disclosure of Unlabeled Use
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)–approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.
Copyright Statement
Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2022 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.
CME Questions?
Contact us at CME@VindicoCME.com
Expires: March 29, 2023
Accredited By
This continuing medical education activity is provided by
Target Audience
The intended audience for this activity is rheumatologists, hospitalists, critical care physicians, intensivists, immunologists, infectious disease specialists, pulmonologists, and other health care professionals involved in the management of patients hospitalized with COVID-19.
Learning Objectives
Upon successful completion of the activity, participants should be better able to:
- Evaluate the latest data regarding immune-based therapies, including glucocorticoids, JAK inhibitors, and other targeted therapies for the management of patients with COVID-19.
- Recognize how variables such as disease severity, comorbidities, and immunologic endotypes may impact the management of patients with COVID-19.
Activity Description
In this 4-part Curbside Consults video series, experts from infectious disease, pulmonology, and rheumatology will review clinical cases across the spectrum of COVID-19 disease. Strategies will be discussed for the prevention and management of severe COVID-19–associated hyperinflammation and respiratory damage.
Statement of Educational Need
The COVID-19 pandemic has led to an unprecedented health care crisis with widespread global morbidity and mortality. Severe COVID-19 is characterized by a hyperinflammatory state and significant pulmonary disease that can result in respiratory failure and organ damage. Targeted immunomodulatory treatments can reduce the risk of disease progression and death in hospitalized patients with COVID-19. Recent advances have spurred unprecedented levels of ongoing clinical research, creating a substantial challenge for clinicians to stay up to date on the latest evidence-based care and rapidly evolving treatment guidelines.
Faculty
Leonard H. Calabrese, DO
Professor of Medicine
Cleveland Clinic Lerner College of Medicine
Case Western Reserve University
R.J. Fasenmyer Chair of Clinical Immunology
Cleveland Clinic
Cleveland, OH
Relevant Financial Disclosure:
Consultant: AbbVie, Bristol-Myers Squibb, Genentech, Gilead, GlaxoSmithKline, Lilly, Pfizer, Regeneron
Speaker Contracted by Ineligible Company: AbbVie, AstraZeneca, GlaxoSmithKline
Phyllis C. Tien, MD
Associate Professor of Medicine
University of California, San Francisco
San Francisco VA Medical Center, Infectious Disease Section
San Francisco, CA
Relevant Financial Disclosure:
Independent Research Contractor (paid to institution): Gilead, Lilly, Merck
Reviewer
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.
Vindico Medical Education Staff
Disclosure: No relevant financial relationships to disclose.
Signed Disclosures are on file at Vindico Medical Education, Office
of Medical Affairs and Compliance.
Conflict of Interest Policy/Disclosure Statement
Vindico Medical Education adheres to the Accreditation Council for Continuing Medical Education’s (ACCME) Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers, or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Accreditation Statement
Vindico Medical Education is accredited by the ACCME to provide continuing medical education for physicians.
Designation of Credit
Vindico Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Instructions for Receiving Credit
To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 100% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.
Statement of Commercial Support
This activity is supported by an educational grant from Lilly.
Disclaimer Statement/Disclosure of Unlabeled Use
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)–approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.
Copyright Statement
Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2022 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.
CME Questions?
Contact us at CME@VindicoCME.com
Case Conundrums in COVID-19: A Patient With COVID-19 Experiencing Hyperinflammation
StartExpires: March 29, 2023
Accredited By
This continuing medical education activity is provided by
Target Audience
The intended audience for this activity is rheumatologists, hospitalists, critical care physicians, intensivists, immunologists, infectious disease specialists, pulmonologists, and other health care professionals involved in the management of patients hospitalized with COVID-19.
Learning Objectives
Upon successful completion of the activity, participants should be better able to:
- Evaluate the latest data regarding immune-based therapies, including glucocorticoids, JAK inhibitors, and other targeted therapies for the management of patients with COVID-19.
- Recognize how variables such as disease severity, comorbidities, and immunologic endotypes may impact the management of patients with COVID-19.
Activity Description
In this 4-part Curbside Consults video series, experts from infectious disease, pulmonology, and rheumatology will review clinical cases across the spectrum of COVID-19 disease. Strategies will be discussed for the prevention and management of severe COVID-19–associated hyperinflammation and respiratory damage.
Statement of Educational Need
The COVID-19 pandemic has led to an unprecedented health care crisis with widespread global morbidity and mortality. Severe COVID-19 is characterized by a hyperinflammatory state and significant pulmonary disease that can result in respiratory failure and organ damage. Targeted immunomodulatory treatments can reduce the risk of disease progression and death in hospitalized patients with COVID-19. Recent advances have spurred unprecedented levels of ongoing clinical research, creating a substantial challenge for clinicians to stay up to date on the latest evidence-based care and rapidly evolving treatment guidelines.
Faculty
Leonard H. Calabrese, DO
Professor of Medicine
Cleveland Clinic Lerner College of Medicine
Case Western Reserve University
R.J. Fasenmyer Chair of Clinical Immunology
Cleveland Clinic
Cleveland, OH
Relevant Financial Disclosure:
Consultant: AbbVie, Bristol-Myers Squibb, Genentech, Gilead, GlaxoSmithKline, Lilly, Pfizer, Regeneron
Speaker Contracted by Ineligible Company: AbbVie, AstraZeneca, GlaxoSmithKline
Randy Q. Cron, MD, PhD
Professor of Pediatrics
Arthritis Foundation, Alabama Chapter Endowed Chair in Pediatric Rheumatology
University of Alabama at Birmingham Heersink School of Medicine
Birmingham, AL
Relevant Financial Disclosure:
Advisor: Sobi
Consultant: Sironax, Sobi
Speaker Contracted by Ineligible Company: Sobi
Independent Research Contractor: Sobi
Adjudication Committee Chair: Pfizer
Reviewer
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.
Vindico Medical Education Staff
Disclosure: No relevant financial relationships to disclose.
Signed Disclosures are on file at Vindico Medical Education, Office
of Medical Affairs and Compliance.
Conflict of Interest Policy/Disclosure Statement
Vindico Medical Education adheres to the Accreditation Council for Continuing Medical Education’s (ACCME) Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers, or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Accreditation Statement
Vindico Medical Education is accredited by the ACCME to provide continuing medical education for physicians.
Designation of Credit
Vindico Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Instructions for Receiving Credit
To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 100% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.
Statement of Commercial Support
This activity is supported by an educational grant from Lilly.
Disclaimer Statement/Disclosure of Unlabeled Use
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)–approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.
Copyright Statement
Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2022 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.
CME Questions?
Contact us at CME@VindicoCME.com
Expires: March 29, 2023
Accredited By
This continuing medical education activity is provided by
Target Audience
The intended audience for this activity is rheumatologists, hospitalists, critical care physicians, intensivists, immunologists, infectious disease specialists, pulmonologists, and other health care professionals involved in the management of patients hospitalized with COVID-19.
Learning Objectives
Upon successful completion of the activity, participants should be better able to:
- Evaluate the latest data regarding immune-based therapies, including glucocorticoids, JAK inhibitors, and other targeted therapies for the management of patients with COVID-19.
- Recognize how variables such as disease severity, comorbidities, and immunologic endotypes may impact the management of patients with COVID-19.
Activity Description
In this 4-part Curbside Consults video series, experts from infectious disease, pulmonology, and rheumatology will review clinical cases across the spectrum of COVID-19 disease. Strategies will be discussed for the prevention and management of severe COVID-19–associated hyperinflammation and respiratory damage.
Statement of Educational Need
The COVID-19 pandemic has led to an unprecedented health care crisis with widespread global morbidity and mortality. Severe COVID-19 is characterized by a hyperinflammatory state and significant pulmonary disease that can result in respiratory failure and organ damage. Targeted immunomodulatory treatments can reduce the risk of disease progression and death in hospitalized patients with COVID-19. Recent advances have spurred unprecedented levels of ongoing clinical research, creating a substantial challenge for clinicians to stay up to date on the latest evidence-based care and rapidly evolving treatment guidelines.
Faculty
Leonard H. Calabrese, DO
Professor of Medicine
Cleveland Clinic Lerner College of Medicine
Case Western Reserve University
R.J. Fasenmyer Chair of Clinical Immunology
Cleveland Clinic
Cleveland, OH
Relevant Financial Disclosure:
Consultant: AbbVie, Bristol-Myers Squibb, Genentech, Gilead, GlaxoSmithKline, Lilly, Pfizer, Regeneron
Speaker Contracted by Ineligible Company: AbbVie, AstraZeneca, GlaxoSmithKline
Randy Q. Cron, MD, PhD
Professor of Pediatrics
Arthritis Foundation, Alabama Chapter Endowed Chair in Pediatric Rheumatology
University of Alabama at Birmingham Heersink School of Medicine
Birmingham, AL
Relevant Financial Disclosure:
Advisor: Sobi
Consultant: Sironax, Sobi
Speaker Contracted by Ineligible Company: Sobi
Independent Research Contractor: Sobi
Adjudication Committee Chair: Pfizer
Reviewer
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.
Vindico Medical Education Staff
Disclosure: No relevant financial relationships to disclose.
Signed Disclosures are on file at Vindico Medical Education, Office
of Medical Affairs and Compliance.
Conflict of Interest Policy/Disclosure Statement
Vindico Medical Education adheres to the Accreditation Council for Continuing Medical Education’s (ACCME) Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers, or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Accreditation Statement
Vindico Medical Education is accredited by the ACCME to provide continuing medical education for physicians.
Designation of Credit
Vindico Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Instructions for Receiving Credit
To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 100% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.
Statement of Commercial Support
This activity is supported by an educational grant from Lilly.
Disclaimer Statement/Disclosure of Unlabeled Use
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)–approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.
Copyright Statement
Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2022 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.
CME Questions?
Contact us at CME@VindicoCME.com
Managing Severe COVID-19 in the Hospital Setting: An Interprofessional Approach
StartActivity Details
0.5 ANCC Contact Hour(s)
0.5 IPCE Credit(s)™
0.5 ABIM MOC Point(s)
Expires: February 10, 2023
Provided By
RMEI Medical Education, LLC
Target Audience
This activity is intended for emergency medicine, hospital medicine, infectious disease, internal medicine, and pediatric clinicians (MD/NP/PA/Nurses) involved in the treatment of patients with severe COVID-19 infection.
Learning Objectives
Upon completion of this activity, participants should be better able to:
- Assess disease severity and implications in patients with COVID-19
- Incorporate emergency use authorization status and available clinical trial data into the selection of treatment for patients hospitalized with COVID-19
- Integrate the unique roles and responsibilities of interprofessional care team members in the management of severe COVID-19 in hospitalized patients
Activity Description
“I was dying … and I was dying alone,” says Nancy, recalling her lonely isolation in the intensive care unit as one of the earlier victims of COVID-19 in her region. This dynamic panel features an interprofessional lineup of experts who will debate and discuss data, guidelines, and literature on the treatment of severe COVID-19 in the hospital setting and what it all means for your practice and patients. Additionally, they are joined by Nancy who survived the earliest days of COVID-19 in the United States and will share her learning moments with the panel and learners.
Chair
Director, Clinical Infectious Diseases Research and MultiSpecialties
Clinical Associate Professor, Medicine (Tulane University)
Associate Professor, University of Queensland/Ochsner Clinical School, Brisbane, Australia
Ochsner Health
New Orleans, LA
Faculty
Chief, Division of Infectious Diseases
Vice-Chair, Faculty Development
Professor, Medicine
Director, San Antonio Center for Medical Mycology
UT Health San Antonio
San Antonio, TX
Advanced Practice Provider, Pulmonary Critical Care
Chairperson, System Critical Care Integration Council
Ochsner Medical Center
Ochsner Health
New Orleans, LA
Disclosure of Financial Relationships
RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy.
Faculty
Julia B. García-Díaz, MD, MSc, FACP, FIDSA, CPI, has no relevant
financial relationships with ineligible companies to disclose.
Thomas F. Patterson, MD, FACP, FIDSA, has relevant financial relationships with Appili, Basilea, Gilead, Mayne, Merck, Pfizer, Scynexis, Sfunga (Consultant); Cidara, F2G (Researcher).
Fiona A. Winterbottom, DNP, MSN, APRN, ACNS-BC, ACHPN, CCRN, has relevant financial relationships with Baxter (Advisor); Zoll (Speaker/Speaker’s Bureau).
Patient participating in this activity has no relevant financial relationship(s) with ineligible companies to disclose.
All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.
Planners and Managers
RMEI Medical Education, LLC planners and managers have no relevant financial
relationship(s) with ineligible companies to disclose.
Joint Accreditation Statement
In support
of improving patient care, RMEI Medical Education, LLC is jointly accredited
by the Accreditation Council for Continuing Medical Education (ACCME), the
Accreditation Council for Pharmacy Education (ACPE), and the American Nurses
Credentialing Center (ANCC), to provide continuing education for the
healthcare team.
Designation of Credit
Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum
of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only
the credit commensurate with the extent of their participation in the
activity.
Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education
activity is 0.5 contact hour(s).
American Board of Internal Medicine Maintenance of
Certification
Successful
completion of this CME activity, which includes participation in the
evaluation component, enables the participant to earn up to 0.5 medical
knowledge MOC point(s) in the American Board of Internal Medicine’s (ABIM)
Maintenance of Certification (MOC) program. Participants will earn MOC points
equivalent to the amount of CME credits claimed for the activity. It is the
CME activity provider’s responsibility to submit participant completion
information to ACCME for the purpose of granting ABIM MOC credit.
Interprofessional Continuing
Education
This
activity was planned by and for the healthcare team, and learners will
receive 0.5 Interprofessional Continuing Education (IPCE) credit for learning
and change.
Instructions for Receiving Credit
In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 75% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at contact@rmei.com.
Users must:
- Read the learning objectives and faculty disclosures
- Participate in the activity
- Complete the activity evaluation and attest to credit
Physicians claiming ABIM MOC points must provide ABIM ID and month/date of birth and score 75% or higher on the post-test.
For Physicians: MOC points will be submitted to ABIM profiles within 4 weeks of completion.
There is no fee for this educational activity.
Your Feedback is Important!
COMPLETE THE EVALUATION FORM
AND YOU WILL BE ENTERED INTO A DRAWING FOR A $100* AMAZON GIFT
CARD!
*The expense for this gift card is solely funded by RMEI Medical Education,
LLC.
No supporter funding was used for the expense of this gift card.
Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly
accredited provider. The winner will be selected via automated random drawing
on a quarterly basis from among all eligible entries and notified through the
contact information provided. In accordance with our privacy policy, we do
not share your information with any third parties. By entering the
sweepstakes, you grant RMEI permission to use your e-mail address to reach
you for notification and prize fulfillment. Only individuals who complete the
evaluation forms and provide contact information will be eligible to win.
Open to those who have a US postal address and who are 18 years or older.
Only one prize per person and per household will be awarded. The prize will
be a $100 Amazon gift card.
Statement of Commercial Support
This activity is supported by an educational grant from Genentech, a member of the Roche Group.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Activity Details
0.5 ANCC Contact Hour(s)
0.5 IPCE Credit(s)™
0.5 ABIM MOC Point(s)
Expires: February 10, 2023
Provided By
RMEI Medical Education, LLC
Target Audience
This activity is intended for emergency medicine, hospital medicine, infectious disease, internal medicine, and pediatric clinicians (MD/NP/PA/Nurses) involved in the treatment of patients with severe COVID-19 infection.
Learning Objectives
Upon completion of this activity, participants should be better able to:
- Assess disease severity and implications in patients with COVID-19
- Incorporate emergency use authorization status and available clinical trial data into the selection of treatment for patients hospitalized with COVID-19
- Integrate the unique roles and responsibilities of interprofessional care team members in the management of severe COVID-19 in hospitalized patients
Activity Description
“I was dying … and I was dying alone,” says Nancy, recalling her lonely isolation in the intensive care unit as one of the earlier victims of COVID-19 in her region. This dynamic panel features an interprofessional lineup of experts who will debate and discuss data, guidelines, and literature on the treatment of severe COVID-19 in the hospital setting and what it all means for your practice and patients. Additionally, they are joined by Nancy who survived the earliest days of COVID-19 in the United States and will share her learning moments with the panel and learners.
Chair
Director, Clinical Infectious Diseases Research and MultiSpecialties
Clinical Associate Professor, Medicine (Tulane University)
Associate Professor, University of Queensland/Ochsner Clinical School, Brisbane, Australia
Ochsner Health
New Orleans, LA
Faculty
Chief, Division of Infectious Diseases
Vice-Chair, Faculty Development
Professor, Medicine
Director, San Antonio Center for Medical Mycology
UT Health San Antonio
San Antonio, TX
Advanced Practice Provider, Pulmonary Critical Care
Chairperson, System Critical Care Integration Council
Ochsner Medical Center
Ochsner Health
New Orleans, LA
Disclosure of Financial Relationships
RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy.
Faculty
Julia B. García-Díaz, MD, MSc, FACP, FIDSA, CPI, has no relevant
financial relationships with ineligible companies to disclose.
Thomas F. Patterson, MD, FACP, FIDSA, has relevant financial relationships with Appili, Basilea, Gilead, Mayne, Merck, Pfizer, Scynexis, Sfunga (Consultant); Cidara, F2G (Researcher).
Fiona A. Winterbottom, DNP, MSN, APRN, ACNS-BC, ACHPN, CCRN, has relevant financial relationships with Baxter (Advisor); Zoll (Speaker/Speaker’s Bureau).
Patient participating in this activity has no relevant financial relationship(s) with ineligible companies to disclose.
All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.
Planners and Managers
RMEI Medical Education, LLC planners and managers have no relevant financial
relationship(s) with ineligible companies to disclose.
Joint Accreditation Statement
In support
of improving patient care, RMEI Medical Education, LLC is jointly accredited
by the Accreditation Council for Continuing Medical Education (ACCME), the
Accreditation Council for Pharmacy Education (ACPE), and the American Nurses
Credentialing Center (ANCC), to provide continuing education for the
healthcare team.
Designation of Credit
Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum
of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only
the credit commensurate with the extent of their participation in the
activity.
Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education
activity is 0.5 contact hour(s).
American Board of Internal Medicine Maintenance of
Certification
Successful
completion of this CME activity, which includes participation in the
evaluation component, enables the participant to earn up to 0.5 medical
knowledge MOC point(s) in the American Board of Internal Medicine’s (ABIM)
Maintenance of Certification (MOC) program. Participants will earn MOC points
equivalent to the amount of CME credits claimed for the activity. It is the
CME activity provider’s responsibility to submit participant completion
information to ACCME for the purpose of granting ABIM MOC credit.
Interprofessional Continuing
Education
This
activity was planned by and for the healthcare team, and learners will
receive 0.5 Interprofessional Continuing Education (IPCE) credit for learning
and change.
Instructions for Receiving Credit
In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 75% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at contact@rmei.com.
Users must:
- Read the learning objectives and faculty disclosures
- Participate in the activity
- Complete the activity evaluation and attest to credit
Physicians claiming ABIM MOC points must provide ABIM ID and month/date of birth and score 75% or higher on the post-test.
For Physicians: MOC points will be submitted to ABIM profiles within 4 weeks of completion.
There is no fee for this educational activity.
Your Feedback is Important!
COMPLETE THE EVALUATION FORM
AND YOU WILL BE ENTERED INTO A DRAWING FOR A $100* AMAZON GIFT
CARD!
*The expense for this gift card is solely funded by RMEI Medical Education,
LLC.
No supporter funding was used for the expense of this gift card.
Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly
accredited provider. The winner will be selected via automated random drawing
on a quarterly basis from among all eligible entries and notified through the
contact information provided. In accordance with our privacy policy, we do
not share your information with any third parties. By entering the
sweepstakes, you grant RMEI permission to use your e-mail address to reach
you for notification and prize fulfillment. Only individuals who complete the
evaluation forms and provide contact information will be eligible to win.
Open to those who have a US postal address and who are 18 years or older.
Only one prize per person and per household will be awarded. The prize will
be a $100 Amazon gift card.
Statement of Commercial Support
This activity is supported by an educational grant from Genentech, a member of the Roche Group.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Case-in-Point™ − Cause for Alarm: New Avenues to the Management of Severe Asthma
StartActivity Details
1.0 AANP Contact Hour(s)
Expires: January 18, 2023
Provided By
This activity is jointly provided by Global Education Group and Integritas
Communications.
Target Audience
This activity addresses the needs of clinical immunologists, pulmonologists, and other physicians involved in the management of patients with severe asthma.
Learning Objectives
After completing this activity, the participant should be better able to:
- Describe clinically relevant pathophysiologic processes in severe asthma, including implications for new targeted treatment options
- Comprehensively assess patients with asthma for disease severity, lung function, and treatment responses
- Discuss the mechanisms of action and clinical profiles of new and emerging targeted therapies for severe asthma
- Individualize treatment regimens for patients with severe asthma based on symptoms, phenotypes, and patient preferences
Activity Description
Best practices within the management of severe asthma require the integration of evidence-based guidelines, the latest scientific information, and an accumulation of clinical experience—all of which inform individualized treatment selection and chronic care decisions. To better mirror real-world practice, this Case-in-Point™ severe asthma enduring program will utilize a case-based format to actively engage learners while emphasizing knowledge consolidation and translation. Within the context of these representative, challenging case studies, a multidisciplinary panel of expert faculty will review and discuss key topics including newer insights into type 2 (T2) high and T2 low asthma pathophysiology, the longitudinal assessment of severe disease, and the latest evidence and rationale for the implementation of available and emerging targeted therapies.
Moderator
Professor of Medicine, Robert Wood Johnson Medical School
Vice Chancellor, Translational Medicine and Science
Director, Rutgers Institute for Translational Medicine and Science
Emeritus Professor of Medicine, University of Pennsylvania
Child Health Institute of New Jersey
Rutgers, The State University of New Jersey
New Brunswick, New Jersey
Faculty
Professor of Medicine
Chair, Department of Medicine
The Robert and Irene Flinn Endowed Chair in Medicine
University of Arizona (UA) College of Medicine – Tucson
Deputy Director, UA Health Sciences Asthma and Airway Disease Research Center
Tucson, Arizona
Professor of Medicine
Department of Allergy and Immunology
Department of Otolaryngology – Head and Neck Surgery
Director of Clinical Research
Division of Allergy and Immunology
Northwestern University Feinberg School of Medicine
Chicago, Illinois
Disclosure of Conflicts of Interest
Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.
All relevant financial relationships have been mitigated.
The faculty have the following relevant financial relationships with ineligible companies:
Reynold A. Panettieri, Jr, MD: Consulting Fee: AstraZeneca plc, Bayer AG, Genentech, Inc., Teva Pharmaceutical Industries Ltd.; Contracted Research: ACTIV-1, AstraZeneca plc, Genentech, Inc., Janssen Pharmaceuticals, Medimmune, LLC, Novartis International AG, Origo Biopharma, Teva Pharmaceutical Industries Ltd., Vault Health, Inc.; Speakers Bureau: AstraZeneca plc, Genentech, Inc., Merck & Co., Inc., Sanofi S.A.
Monica Kraft, MD: Consulting Fee: AstraZeneca plc, Sanofi S.A.; Contracted Research: ALA Pharma Ltd., AstraZeneca plc, Chiesi USA, Inc., Sanofi S.A.
Anju T. Peters, MD, MS: Consulting Fee: AstraZeneca plc, GlaxoSmithKline, Novartis International AG, Optinose US, Inc., Regeneron Pharmaceuticals, Inc., Sanofi S.A.; Contracted Research: AstraZeneca plc, Merck & Co., Inc., Optinose US, Inc., Regeneron Pharmaceuticals, Inc., Sanofi S.A.
The following planners and managers have reported no relevant financial relationships with ineligible companies:
Kristin Delisi, NP, Lindsay Borvansky, Andrea Funk, Liddy Knight, Ashley Cann, Celeste Collazo, MD, Rose O’Connor, PhD, CHCP, Jim Kappler, PhD
Physician Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Integritas Communications. Global is accredited by the ACCME to provide continuing medical education for physicians.
Physician Credit Designation
Global designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurse Practitioner Continuing Education
This activity has been planned and implemented in
accordance with the Accreditation Standards of the American Association of
Nurse Practitioners (AANP) through the joint providership of Global Education
Group and Integritas Communications. Global Education Group is accredited by
the American Association of Nurse Practitioners as an approved provider of
nurse practitioner continuing education. Provider number: 110121. This
activity is approved for 1.0 contact hour(s) (which includes 0.2 hour(s) of
pharmacology).
Instructions for Receiving Credit
In order to receive credit for this activity, the participant must complete the preactivity questionnaire, score 75% or better on the post-test, and complete the program evaluation.
Statement of Commercial Support
This activity is supported by an independent educational grant from AstraZeneca.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or
investigational uses of agents that are not indicated by the FDA. Global and
Integritas Communications do not recommend the use of any agent outside of
the labeled indications.
The opinions expressed in the educational activity are those of the faculty
and do not necessarily represent the views of any organization associated
with this activity. Please refer to the official prescribing information for
each product for discussion of approved indications, contraindications, and
warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Term of Offering
This activity was released on January 18, 2022, and is valid for one year. Requests for credit must be made no later than January 18, 2023.
Fee Information & Refund/Cancellation Policy
There is no fee for this educational activity.
Contact Information for Questions About the Activity
Global Contact Information
For information about the accreditation of this program, please contact
Global at 303-395-1782 or cme@globaleducationgroup.com.
Activity Details
1.0 AANP Contact Hour(s)
Expires: January 18, 2023
Provided By
This activity is jointly provided by Global Education Group and Integritas
Communications.
Target Audience
This activity addresses the needs of clinical immunologists, pulmonologists, and other physicians involved in the management of patients with severe asthma.
Learning Objectives
After completing this activity, the participant should be better able to:
- Describe clinically relevant pathophysiologic processes in severe asthma, including implications for new targeted treatment options
- Comprehensively assess patients with asthma for disease severity, lung function, and treatment responses
- Discuss the mechanisms of action and clinical profiles of new and emerging targeted therapies for severe asthma
- Individualize treatment regimens for patients with severe asthma based on symptoms, phenotypes, and patient preferences
Activity Description
Best practices within the management of severe asthma require the integration of evidence-based guidelines, the latest scientific information, and an accumulation of clinical experience—all of which inform individualized treatment selection and chronic care decisions. To better mirror real-world practice, this Case-in-Point™ severe asthma enduring program will utilize a case-based format to actively engage learners while emphasizing knowledge consolidation and translation. Within the context of these representative, challenging case studies, a multidisciplinary panel of expert faculty will review and discuss key topics including newer insights into type 2 (T2) high and T2 low asthma pathophysiology, the longitudinal assessment of severe disease, and the latest evidence and rationale for the implementation of available and emerging targeted therapies.
Moderator
Professor of Medicine, Robert Wood Johnson Medical School
Vice Chancellor, Translational Medicine and Science
Director, Rutgers Institute for Translational Medicine and Science
Emeritus Professor of Medicine, University of Pennsylvania
Child Health Institute of New Jersey
Rutgers, The State University of New Jersey
New Brunswick, New Jersey
Faculty
Professor of Medicine
Chair, Department of Medicine
The Robert and Irene Flinn Endowed Chair in Medicine
University of Arizona (UA) College of Medicine – Tucson
Deputy Director, UA Health Sciences Asthma and Airway Disease Research Center
Tucson, Arizona
Professor of Medicine
Department of Allergy and Immunology
Department of Otolaryngology – Head and Neck Surgery
Director of Clinical Research
Division of Allergy and Immunology
Northwestern University Feinberg School of Medicine
Chicago, Illinois
Disclosure of Conflicts of Interest
Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.
All relevant financial relationships have been mitigated.
The faculty have the following relevant financial relationships with ineligible companies:
Reynold A. Panettieri, Jr, MD: Consulting Fee: AstraZeneca plc, Bayer AG, Genentech, Inc., Teva Pharmaceutical Industries Ltd.; Contracted Research: ACTIV-1, AstraZeneca plc, Genentech, Inc., Janssen Pharmaceuticals, Medimmune, LLC, Novartis International AG, Origo Biopharma, Teva Pharmaceutical Industries Ltd., Vault Health, Inc.; Speakers Bureau: AstraZeneca plc, Genentech, Inc., Merck & Co., Inc., Sanofi S.A.
Monica Kraft, MD: Consulting Fee: AstraZeneca plc, Sanofi S.A.; Contracted Research: ALA Pharma Ltd., AstraZeneca plc, Chiesi USA, Inc., Sanofi S.A.
Anju T. Peters, MD, MS: Consulting Fee: AstraZeneca plc, GlaxoSmithKline, Novartis International AG, Optinose US, Inc., Regeneron Pharmaceuticals, Inc., Sanofi S.A.; Contracted Research: AstraZeneca plc, Merck & Co., Inc., Optinose US, Inc., Regeneron Pharmaceuticals, Inc., Sanofi S.A.
The following planners and managers have reported no relevant financial relationships with ineligible companies:
Kristin Delisi, NP, Lindsay Borvansky, Andrea Funk, Liddy Knight, Ashley Cann, Celeste Collazo, MD, Rose O’Connor, PhD, CHCP, Jim Kappler, PhD
Physician Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Integritas Communications. Global is accredited by the ACCME to provide continuing medical education for physicians.
Physician Credit Designation
Global designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurse Practitioner Continuing Education
This activity has been planned and implemented in
accordance with the Accreditation Standards of the American Association of
Nurse Practitioners (AANP) through the joint providership of Global Education
Group and Integritas Communications. Global Education Group is accredited by
the American Association of Nurse Practitioners as an approved provider of
nurse practitioner continuing education. Provider number: 110121. This
activity is approved for 1.0 contact hour(s) (which includes 0.2 hour(s) of
pharmacology).
Instructions for Receiving Credit
In order to receive credit for this activity, the participant must complete the preactivity questionnaire, score 75% or better on the post-test, and complete the program evaluation.
Statement of Commercial Support
This activity is supported by an independent educational grant from AstraZeneca.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or
investigational uses of agents that are not indicated by the FDA. Global and
Integritas Communications do not recommend the use of any agent outside of
the labeled indications.
The opinions expressed in the educational activity are those of the faculty
and do not necessarily represent the views of any organization associated
with this activity. Please refer to the official prescribing information for
each product for discussion of approved indications, contraindications, and
warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Term of Offering
This activity was released on January 18, 2022, and is valid for one year. Requests for credit must be made no later than January 18, 2023.
Fee Information & Refund/Cancellation Policy
There is no fee for this educational activity.
Contact Information for Questions About the Activity
Global Contact Information
For information about the accreditation of this program, please contact
Global at 303-395-1782 or cme@globaleducationgroup.com.
Clinical Presentation and Identification of CF-ILD: Journey to a Diagnosis of IPF
StartActivity Details
Expires: November 29, 2022
Accredited By
This continuing medical education activity is provided by
Target Audience
The intended audience for this activity is pulmonologists, pathologists, radiologists, and other health care professionals involved in the management of patients with interstitial lung disease.
Learning Objectives
Upon successful completion of these activities, participants should be better able to:
- Describe the disease pathophysiology, prevalence, morbidity and mortality, and signs and symptoms of chronic fibrosing interstitial lung disease (CF-ILD).
- Evaluate optimal treatment strategies for patients with CF-ILD.
Activity Description
In this educational video, Drs. Kevin Flaherty and Marilyn Glassberg discuss the workup and clinical course of a patient with idiopathic pulmonary fibrosis.
Activity Chair
Professor of Medicine
Division of Pulmonary/Critical Care Medicine
Director, Michigan Medicine Interstitial Lung Disease Clinic
University of Michigan
Ann Arbor, MI
Relevant Disclosures:
Consultant: Bellerophon, Boehringer Ingelheim, United Therapeutics
Independent Research Contractor: Boehringer Ingelheim
Faculty
Scientific Advisory Committee
Division Chief, Pulmonary Medicine, Critical Care and Sleep Medicine
University of Arizona College of Medicine
Phoenix, AZ
Relevant Disclosures:
Advisor: Bellerophon Therapeutics
Consultant: Genentech/Roche
Reviewer
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Relevant Disclosures: No relevant financial relationships to disclose.
Vindico Medical Education Staff
Relevant Disclosures: No relevant financial relationships to disclose.
Signed Disclosures are on file at Vindico Medical Education, Office
of Medical Affairs and Compliance.
Conflict of Interest Policy/Disclosure Statement
Vindico Medical Education adheres to the Accreditation Council for Continuing Medical Education’s (ACCME) Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a continuing education activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Accreditation Statement
Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation of Credit
Vindico Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Instructions for Receiving Credit
To participate in this CME activity, you must read the objectives, answer the pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering the posttest question correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ certificate.
Statement of Commercial Support
This activity is supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.
Unlabeled and Investigational Usage
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)–approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.
Copyright Statement
Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.
CME Questions?
Contact us at CME@VindicoCME.com
Activity Details
Expires: November 29, 2022
Accredited By
This continuing medical education activity is provided by
Target Audience
The intended audience for this activity is pulmonologists, pathologists, radiologists, and other health care professionals involved in the management of patients with interstitial lung disease.
Learning Objectives
Upon successful completion of these activities, participants should be better able to:
- Describe the disease pathophysiology, prevalence, morbidity and mortality, and signs and symptoms of chronic fibrosing interstitial lung disease (CF-ILD).
- Evaluate optimal treatment strategies for patients with CF-ILD.
Activity Description
In this educational video, Drs. Kevin Flaherty and Marilyn Glassberg discuss the workup and clinical course of a patient with idiopathic pulmonary fibrosis.
Activity Chair
Professor of Medicine
Division of Pulmonary/Critical Care Medicine
Director, Michigan Medicine Interstitial Lung Disease Clinic
University of Michigan
Ann Arbor, MI
Relevant Disclosures:
Consultant: Bellerophon, Boehringer Ingelheim, United Therapeutics
Independent Research Contractor: Boehringer Ingelheim
Faculty
Scientific Advisory Committee
Division Chief, Pulmonary Medicine, Critical Care and Sleep Medicine
University of Arizona College of Medicine
Phoenix, AZ
Relevant Disclosures:
Advisor: Bellerophon Therapeutics
Consultant: Genentech/Roche
Reviewer
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Relevant Disclosures: No relevant financial relationships to disclose.
Vindico Medical Education Staff
Relevant Disclosures: No relevant financial relationships to disclose.
Signed Disclosures are on file at Vindico Medical Education, Office
of Medical Affairs and Compliance.
Conflict of Interest Policy/Disclosure Statement
Vindico Medical Education adheres to the Accreditation Council for Continuing Medical Education’s (ACCME) Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a continuing education activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Accreditation Statement
Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation of Credit
Vindico Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Instructions for Receiving Credit
To participate in this CME activity, you must read the objectives, answer the pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering the posttest question correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ certificate.
Statement of Commercial Support
This activity is supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.
Unlabeled and Investigational Usage
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)–approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.
Copyright Statement
Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.
CME Questions?
Contact us at CME@VindicoCME.com
Choosing the Optimal Treatment in a Patient With Progressive Fibrosing ILD
StartActivity Details
Expires: November 29, 2022
Accredited By
This continuing medical education activity is provided by
Target Audience
The intended audience for this activity is pulmonologists, pathologists, radiologists, and other health care professionals involved in the management of patients with interstitial lung disease.
Learning Objectives
Upon successful completion of these activities, participants should be better able to:
- Describe the disease pathophysiology, prevalence, morbidity and mortality, and signs and symptoms of chronic fibrosing interstitial lung disease (CF-ILD).
- Evaluate optimal treatment strategies for patients with CF-ILD.
- Review up-to-date clinical data for the management of patients with CF-ILD in the era of COVID-19.
Activity Description
In this educational video, Drs. Kevin Flaherty and Lisa Lancaster discuss the assessment and management of a patient with chronic hypersensitivity pneumonitis.
Activity Chair
Professor of Medicine
Division of Pulmonary/Critical Care Medicine
Director, Michigan Medicine Interstitial Lung Disease Clinic
University of Michigan
Ann Arbor, MI
Relevant Disclosures:
Consultant: Bellerophon, Boehringer Ingelheim, United Therapeutics
Independent Research Contractor: Boehringer Ingelheim
Faculty
Professor of Medicine
Division of Allergy, Pulmonary, and Critical Care Medicine
Director, Vanderbilt Interstitial Lung Disease Program
Vanderbilt University Medical Center
Nashville, TN
Relevant Disclosures:
Advisor: Bellerophon, United Therapeutics
Consultant: Bellerophon, Genentech, United Therapeutics
Speaker Contracted by Ineligible Company: Boehringer Ingelheim, Genentech
Independent Research Contractor (paid to institution): Boehringer Ingelheim, Roche
Reviewer
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Relevant Disclosures: No relevant financial relationships to disclose.
Vindico Medical Education Staff
Relevant Disclosures: No relevant financial relationships to disclose.
Signed Disclosures are on file at Vindico Medical Education, Office
of Medical Affairs and Compliance.
Conflict of Interest Policy/Disclosure Statement
Vindico Medical Education adheres to the Accreditation Council for Continuing Medical Education’s (ACCME) Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a continuing education activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Accreditation Statement
Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation of Credit
Vindico Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Instructions for Receiving Credit
To participate in this CME activity, you must read the objectives, answer the pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering the posttest question correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ certificate.
Statement of Commercial Support
This activity is supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.
Unlabeled and Investigational Usage
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)–approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.
Copyright Statement
Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.
CME Questions?
Contact us at CME@VindicoCME.com
Activity Details
Expires: November 29, 2022
Accredited By
This continuing medical education activity is provided by
Target Audience
The intended audience for this activity is pulmonologists, pathologists, radiologists, and other health care professionals involved in the management of patients with interstitial lung disease.
Learning Objectives
Upon successful completion of these activities, participants should be better able to:
- Describe the disease pathophysiology, prevalence, morbidity and mortality, and signs and symptoms of chronic fibrosing interstitial lung disease (CF-ILD).
- Evaluate optimal treatment strategies for patients with CF-ILD.
- Review up-to-date clinical data for the management of patients with CF-ILD in the era of COVID-19.
Activity Description
In this educational video, Drs. Kevin Flaherty and Lisa Lancaster discuss the assessment and management of a patient with chronic hypersensitivity pneumonitis.
Activity Chair
Professor of Medicine
Division of Pulmonary/Critical Care Medicine
Director, Michigan Medicine Interstitial Lung Disease Clinic
University of Michigan
Ann Arbor, MI
Relevant Disclosures:
Consultant: Bellerophon, Boehringer Ingelheim, United Therapeutics
Independent Research Contractor: Boehringer Ingelheim
Faculty
Professor of Medicine
Division of Allergy, Pulmonary, and Critical Care Medicine
Director, Vanderbilt Interstitial Lung Disease Program
Vanderbilt University Medical Center
Nashville, TN
Relevant Disclosures:
Advisor: Bellerophon, United Therapeutics
Consultant: Bellerophon, Genentech, United Therapeutics
Speaker Contracted by Ineligible Company: Boehringer Ingelheim, Genentech
Independent Research Contractor (paid to institution): Boehringer Ingelheim, Roche
Reviewer
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Relevant Disclosures: No relevant financial relationships to disclose.
Vindico Medical Education Staff
Relevant Disclosures: No relevant financial relationships to disclose.
Signed Disclosures are on file at Vindico Medical Education, Office
of Medical Affairs and Compliance.
Conflict of Interest Policy/Disclosure Statement
Vindico Medical Education adheres to the Accreditation Council for Continuing Medical Education’s (ACCME) Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a continuing education activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Accreditation Statement
Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation of Credit
Vindico Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Instructions for Receiving Credit
To participate in this CME activity, you must read the objectives, answer the pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering the posttest question correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ certificate.
Statement of Commercial Support
This activity is supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.
Unlabeled and Investigational Usage
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)–approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.
Copyright Statement
Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.
CME Questions?
Contact us at CME@VindicoCME.com